Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-κB signaling pathway

Molecular and Cellular Biochemistry

Volumn 330, Issue 1-2, 2009, Pages 39-46

  Yang, Jian ^a   Jiang, Hong ^a   Yang, Jun ^b   Ding, Jia Wang ^c   Chen, Li Hua ^b   Li, Song ^c   Zhang, Xiao Dong ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b CHINA THREE GORGES UNIVERSITY   (China)

^c Yichang Central People's Hospital   (China)

Author keywords

Inflammation; Nuclear factor kappa B; Reperfusion injury; Toll like receptors; Valsartan

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CREATINE KINASE; CREATINE KINASE MB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; TOLL LIKE RECEPTOR 4; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; EXPERIMENTAL RAT; GENE EXPRESSION REGULATION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HISTOPATHOLOGY; LOW DRUG DOSE; MALE; MICROSCOPY; NONHUMAN; QUANTITATIVE STUDY; RAT; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; STAINING; WESTERN BLOTTING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; INFLAMMATION MEDIATORS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL REPERFUSION INJURY; NF-KAPPA B; RATS; SIGNAL TRANSDUCTION; TETRAZOLES; TOLL-LIKE RECEPTOR 4; TREATMENT OUTCOME; VALINE;

RATTUS;

EID: 73349124780     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-009-0098-1     Document Type: Article

References (42)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) 1986 Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction Lancet 1 397 402
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group 1988 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 2 349 360
3. CP Cannon CM Gibson CT Lambrew DA Shoultz D Levy WJ French, et al. 2000 Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction JAMA 283 2941 2947 10.1001/jama.283.22.2941 10.1001/jama.283.22.2941 1:STN:280:DC%2BD3czisFKksQ%3D%3D 10865271
4. F Ribichini W Wijns 2002 Acute myocardial infarction: reperfusion treatment Heart 88 298 305 10.1136/heart.88.3.298 10.1136/heart.88.3.298 12181231
5. PR Hansen 1995 Myocardial reperfusion injury: experimental evidence and clinical relevance Eur Heart J 16 734 740 1:STN:280:DyaK28%2Fns1WjsQ%3D%3D 7588916
6. AP Vakeva A Agah SA Rollins LA Matis L Li GL Stahl 1998 Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy Circulation 97 2259 2267 1:CAS:528:DyaK1cXjvF2qs70%3D 9631876
7. NG Frangogiannis CW Smith ML Entman 2002 The inflammatory response in myocardial infarction Cardiovasc Res 53 31 47 10.1016/S0008-6363(01)00434-5 10.1016/S0008-6363(01)00434-5 1:CAS:528:DC%2BD3MXptVahsb0%3D 11744011 (Pubitemid 34020764)
8. CN Serhan A Jain S Marleau C Clish A Kantarci B Behbehani, et al. 2003 Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators J Immunol 171 6856 6865 1:CAS:528:DC%2BD3sXpsV2rtbc%3D 14662892
9. CN Serhan 2005 Novel omega-3-derived local mediators in anti-inflammation and resolution Pharmacol Ther 105 7 21 10.1016/j.pharmthera.2004.09.002 10.1016/j.pharmthera.2004.09.002 1:CAS:528:DC%2BD2MXjsVGh 15626453 (Pubitemid 40044765)
10. R Medzhitov P Preston-Hurlburt CA Janeway Jr 1997 A human homologue of the Drosophila toll protein signals activation of adaptive immunity Nature 388 394 397 10.1038/41131 10.1038/41131 1:CAS:528:DyaK2sXkvVChurc%3D 9237759 (Pubitemid 27334820)
11. K Miyake 2007 Innate immune sensing of pathogens and danger signals by cell surface toll-like receptors Semin Immunol 19 3 10 10.1016/j.smim.2006.12. 002 10.1016/j.smim.2006.12.002 1:CAS:528:DC%2BD2sXjslGrsLc%3D 17275324 (Pubitemid 46498750)
12. S Akira K Takeda T Kaisho 2001 Toll-like receptors: critical proteins linking innate and acquired immunity Nat Immunol 2 675 680 10.1038/90609 10.1038/90609 1:CAS:528:DC%2BD3MXlslGjtLs%3D 11477402 (Pubitemid 32747155)
13. G Baumgarten P Knuefermann N Nozaki N Sivasubramanian DL Mann JG Vallejo 2001 In vivo expression of proinflammatory mediators in the adult heart after endotoxin administration: the role of toll-like receptor-4 J Infect Dis 183 1617 1624 10.1086/320712 10.1086/320712 1:CAS:528:DC%2BD3MXktl2ksbY%3D 11343210 (Pubitemid 32466699)
14. J Oyama C Blais Jr X Liu M Pu L Kobzik RA Kelly, et al. 2004 Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice Circulation 109 784 789 10.1161/01.CIR.0000112575.66565.84 10.1161/01.CIR. 0000112575.66565.84 1:CAS:528:DC%2BD2cXhtFWltbw%3D 14970116 (Pubitemid 38222900)
15. AJ Chong A Shimamoto CR Hampton H Takayama DJ Spring CL Rothnie, et al. 2004 Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart J Thorac Cardiovasc Surg 128 170 179 10.1016/j.jtcvs.2003.11.036 10.1016/j.jtcvs.2004.03.049 1:CAS:528:DC%2BD2cXntVGqurc%3D 15282452 (Pubitemid 38969797)
16. J Yang J Yang JW Ding LH Chen YL Wang S Li, et al. 2008 Sequential expression of TLR4 and its effects on the myocardium of rats with myocardial ischemia-reperfusion injury Inflammation 31 304 312 10.1007/s10753-008-9079-x 10.1007/s10753-008-9079-x 1:CAS:528:DC%2BD1cXht1Sqs7zF 18677579
17. B Dahlöf RB Devereux SE Kjeldsen S Julius G Beevers U de Faire, et al. 2002 Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 995 1003 10.1016/S0140-6736(02)08089-3 10.1016/S0140- 6736(02)08089-3 11937178 (Pubitemid 34286536)
18. HR Brunner H Gavras 2002 Angiotensin blockade for hypertension: a promise fulfilled Lancet 359 990 992 10.1016/S0140-6736(02)08062-5 10.1016/S0140- 6736(02)08062-5 11937175 (Pubitemid 34286533)
19. F Zannad R Fay 2007 Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies Fundam Clin Pharmacol 21 181 190 10.1111/j.1472-8206.2007. 00464.x 10.1111/j.1472-8206.2007.00464.x 1:CAS:528:DC%2BD2sXltVakt7Y%3D 17391291 (Pubitemid 46495939)
20. S Navalkar S Parthasarathy N Santanam BV Khan 2001 Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis J Am Coll Cardiol 37 440 444 10.1016/S0735-1097(00)01138-4 10.1016/S0735-1097(00)01138-4 1:CAS:528: DC%2BD3MXhsl2jtLY%3D 11216960
21. S Cianchetti A Del Fiorentino R Colognato R Di Stefano F Franzoni R Pedrinelli 2008 Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells Atherosclerosis 198 22 28 10.1016/j.atherosclerosis.2007.09.013 10.1016/j.atherosclerosis.2007.09.013 1:CAS:528:DC%2BD1cXktFClsrk%3D 17950296
22. R Candido TJ Allen M Lassila Z Cao V Thallas ME Cooper, et al. 2004 Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis Circulation 109 1536 1542 10.1161/01.CIR.0000124061.78478.94 10.1161/01.CIR.0000124061.78478.94 1:CAS:528:DC%2BD2cXisVGmsbg%3D 15023892 (Pubitemid 38420183)
23. L Sironi P Gelosa U Guerrini C Banfi V Crippa M Brioschi, et al. 2004 Anti-inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall J Pharmacol Exp Ther 311 989 995 10.1124/jpet.104.072066 10.1124/jpet.104.072066 1:CAS:528:DC%2BD2cXhtVKmtLzJ 15302895 (Pubitemid 39612703)
24. J Varagic ED Frohlich D Susic J Ahn L Matavelli B López, et al. 2008 AT1 receptor antagonism attenuates target organ effects of salt excess in SHRs without affecting pressure Am J Physiol Heart Circ Physiol 294 H853 H858 10.1152/ajpheart.00737.2007 10.1152/ajpheart.00737.2007 1:CAS:528: DC%2BD1cXit1ylsb8%3D 18055516 (Pubitemid 351253296)
25. YC Chan PS Leung 2007 Angiotensin II type 1 receptor-dependent nuclear factor-kappaB activation-mediated proinflammatory actions in a rat model of obstructive acute pancreatitis J Pharmacol Exp Ther 323 10 18 10.1124/jpet.107.124891 10.1124/jpet.107.124891 1:CAS:528:DC%2BD2sXhtFahsLnP 17616560 (Pubitemid 47443256)
26. N Maulik RM Engelman JA Rousou JE Flack III D Deaton DK Das 1999 Ischemic preconditioning reduces apoptosis by upregulating anti-death gene Bcl-2 Circulation 100 II369 II375 1:STN:280:DC%2BD3c%2FjslSksg%3D%3D 10567332
27. JH Marino P Cook KS Miller 2003 Accurate and statistically verified quantification of relative mRNA abundances using SYBR Green I and real-time RT-PCR J Immunol Methods 283 291 306 10.1016/S0022-1759(03)00103-0 10.1016/S0022-1759(03)00103-0 1:CAS:528:DC%2BD3sXptlOksLo%3D 14659920 (Pubitemid 37501077)
28. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034
29. D Altavilla A Saitta S Guarini M Galeano G Squadrito D Cucinotta, et al. 2001 Oxidative stress causes nuclear factor-kappaB activation in acute hypovolemic hemorrhagic shock Free Radic Biol Med 30 1055 1066 10.1016/S0891-5849(01)00492-0 10.1016/S0891-5849(01)00492-0 1:CAS:528: DC%2BD3MXjsFegsrc%3D 11369495 (Pubitemid 32441830)
30. YQ Zheng W Wei 2005 Total glucosides of paeony suppresses adjuvant arthritis in rats and intervenes cytokine-signaling between different types of synoviocytes Int Immunopharmacol 5 1560 1573 10.1016/j.intimp.2005.03.010 10.1016/j.intimp.2005.03.010 1:CAS:528:DC%2BD2MXmtFSnsrg%3D 16023608 (Pubitemid 40967914)
31. S Zeuke AJ Ulmer S Kusumoto HA Katus H Heine 2002 TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS Cardiovasc Res 56 126 134 10.1016/S0008-6363(02)00512-6 10.1016/S0008-6363(02) 00512-6 1:CAS:528:DC%2BD38XntVWqs7s%3D 12237173 (Pubitemid 35247809)
32. S Nemoto JG Vallejo P Knuefermann A Misra G Defreitas BA Carabello, et al. 2002 Escherichia coli LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart Am J Physiol Heart Circ Physiol 282 H2316 H2323 1:CAS:528:DC%2BD38Xks12nt7o%3D 12003842
33. AA Beg 2002 Endogenous ligands of toll-like receptors: implications for regulating inflammatory and immune responses Trends Immunol 23 509 512 10.1016/S1471-4906(02)02317-7 10.1016/S1471-4906(02)02317-7 1:CAS:528: DC%2BD38XotVKksbs%3D 12401394 (Pubitemid 35223541)
34. B Dybdahl A Wahba E Lien TH Flo A Waage N Qureshi, et al. 2002 Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4 Circulation 105 685 690 10.1161/hc0602.103617 10.1161/hc0602.103617 1:CAS:528:DC%2BD38XitFais70%3D 11839622 (Pubitemid 34157370)
35. D Altavilla B Deodato GM Campo M Arlotta M Miano G Squadrito, et al. 2000 IRFI 042, a novel dual vitamin E-like antioxidant, inhibits activation of nuclear factor-kappaB and reduces the inflammatory response in myocardial ischemia-reperfusion injury Cardiovasc Res 47 515 528 10.1016/S0008-6363(00) 00124-3 10.1016/S0008-6363(00)00124-3 1:CAS:528:DC%2BD3cXlvFWit7o%3D 10963724 (Pubitemid 30646073)
36. A Shimamoto AJ Chong M Yada S Shomura H Takayama AJ Fleisig, et al. 2006 Inhibition of toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury Circulation 114 I270 I274 10.1161/CIRCULATIONAHA. 105.000901 10.1161/CIRCULATIONAHA.105.000901 16820585 (Pubitemid 44297162)
37. PM Ridker E Danielson N Rifai RJ Glynn Val-MARC Investigators 2006 Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial Hypertension 48 73 79 10.1161/01.HYP.0000226046.58883.32 10.1161/01.HYP.0000226046.58883.32 1:CAS:528:DC%2BD28XlvVSmtL8%3D 16714425
38. EA Mueller WS Griffin K Wildenthal 1977 Isoproterenol-induced cardiomyopathy: changes in cardiac enzymes and protection by methylprednisolone J Mol Cell Cardiol 9 565 578 10.1016/S0022-2828(77)80371-4 10.1016/S0022- 2828(77)80371-4 1:CAS:528:DyaE2sXltFWlsb8%3D 894732
39. JP van Kats DJ Duncker DB Haitsma MP Schuijt R Niebuur R Stubenitsky, et al. 2000 Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II Circulation 102 1556 1563 11004147
40. JS Silvestre C Heymes A Oubénaïssa V Robert B Aupetit-Faisant A Carayon, et al. 1999 Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis Circulation 99 2694 2701 1:CAS:528:DyaK1MXjvVKmtrY%3D 10338465
41. Q Dai M Xu M Yao B Sun 2007 Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats Br J Pharmacol 152 1042 1048 10.1038/sj.bjp.0707454 10.1038/sj.bjp.0707454 1:CAS:528: DC%2BD2sXhtlCrsbnL 17922026 (Pubitemid 350166045)
42. H Seeger AO Mueck TH Lippert 2000 Effects of valsartan and 17 beta-estradiol on the oxidation of low-density lipoprotein in vitro Coron Artery Dis 11 347 349 10.1097/00019501-200006000-00008 10.1097/00019501-200006000- 00008 1:STN:280:DC%2BD3cvptlakug%3D%3D 10860178 (Pubitemid 30410232)